{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:42:30Z","timestamp":1786207350223,"version":"build-2736575974"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The potential safety and efficacy of the psychedelic 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has been researched in phase 2 and phase 3 clinical trials. We examined the occurrence and role of mystical experiences in MDMA-AT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were sourced from two phase 2 randomized trials of MDMA-AT for chronic PTSD, in which participants received two sessions with either MDMA or active placebo, in conjunction with psychotherapy. The Mystical Experience Questionnaire 30-item version (MEQ30) was administered after each MDMA session. The association of mystical experiences and PTSD symptom severity (Clinician Administered PTSD Scale for DSM-IV (CAPS-IV)) was analyzed using multilevel regression and mediation analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Fifty-three participants with chronic PTSD were included. Standard doses of MDMA (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200939) were associated with significantly higher mean MEQ30 scores (M\u2009=\u200963.1, SE\u2009=\u20094.9; 42.1% of maximum) compared to active placebo (M\u2009=\u200924.7, SE\u2009=\u20095.5; 16.4%),\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001. Mediation analysis revealed a significant indirect effect of the MEQ30 Positive Mood subscale on symptom reduction (\n                      <jats:italic toggle=\"yes\">b<\/jats:italic>\n                      \u2009=\u2009\u20130.170, 95% CI (\u20130.353, \u20130.007)), while the MEQ total score and other subscales showed smaller, non-significant indirect effects on CAPS-IV scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>MEQ30 scores were significantly higher for MDMA sessions than for active placebo sessions in patients undergoing MDMA-assisted therapy for chronic PTSD. Among mystical-type experiences, the positive mood subscale, rather than full mystical-type states, appeared to contribute most to the mitigation of PTSD symptoms. These findings should be interpreted with caution due to the limited sample size and secondary nature of the analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261464502","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:20:17Z","timestamp":1786072817000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6395-4016","authenticated-orcid":false,"given":"Tijmen P.L.","family":"Bostoen","sequence":"first","affiliation":[{"name":"ARQ National Psychotrauma Center, ARQ Centrum\u201945, The Netherlands"},{"name":"Department of Psychiatry, Leiden University Medical Center, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Krediet","sequence":"additional","affiliation":[{"name":"ARQ National Psychotrauma Center, ARQ Centrum\u201945, The Netherlands"},{"name":"Department of Psychiatry, Leiden University Medical Center, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3231-1383","authenticated-orcid":false,"given":"Annette M.","family":"van Schagen","sequence":"additional","affiliation":[{"name":"ARQ National Psychotrauma Center, ARQ Centrum\u201945, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3235-1633","authenticated-orcid":false,"given":"Nic J.A.","family":"van der Wee","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Leiden University Medical Center, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8874-2292","authenticated-orcid":false,"given":"Erik J.","family":"Giltay","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Leiden University Medical Center, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"e_1_3_3_2_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text rev. (DSM-IV-TR). American Psychiatric Association.","edition":"4"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Barrett FS Johnson MW Griffiths RR (2015) Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology 29(11): 1182\u20131190. https:\/\/doi.org\/10.1177\/0269881115609019","DOI":"10.1177\/0269881115609019"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Blake DD Weathers FW Nagy LM et al. (1995) The development of a clinician-administered PTSD scale. Journal of Traumatic Stress 8: 75\u201390. https:\/\/doi.org\/10.1002\/jts.2490080106","DOI":"10.1002\/jts.2490080106"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Bogenschutz MP Forcehimes AA Pommy JA et al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29(3): 289\u2013299. https:\/\/doi.org\/10.1177\/0269881114565144","DOI":"10.1177\/0269881114565144"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Feduccia AA Mithoefer MC (2018) MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Progress in Neuro-Psychopharmacology and Biological Psychiatry 84: 221\u2013228. https:\/\/doi.org\/10.1016\/j.pnpbp.2018.03.003","DOI":"10.1016\/j.pnpbp.2018.03.003"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Garcia-Romeu A Griffiths RR Johnson MW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Research Reviews 7(3): 157\u2013164. https:\/\/doi.org\/10.2174\/1874473708666150107121331","DOI":"10.2174\/1874473708666150107121331"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"G\u00f6tz M O\u2019Boyle EH Gonzalez-Mul\u00e9 E et al. (2021) The \u201cGoldilocks Zone\u201d: (too) many confidence intervals in tests of mediation just exclude zero. Psychological Bulletin 147(1): 95\u2013114. https:\/\/doi.org\/10.1037\/bul0000311","DOI":"10.1037\/bul0000315"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Griffiths RR Johnson MW Carducci MA et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30(12): 1181\u20131197. https:\/\/doi.org\/10.1177\/0269881116675513","DOI":"10.1177\/0269881116675513"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Holze F Gasser P M\u00fcller F et al. (2023) Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized double-blind placebo-controlled phase II study. Biological Psychiatry 93(3): 215\u2013223. https:\/\/doi.org\/10.1016\/j.biopsych.2022.08.025","DOI":"10.1016\/j.biopsych.2022.08.025"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Holze F Vizeli P M\u00fcller F et al. (2020). Distinct acute effects of LSD MDMA and D-amphetamine in healthy subjects. Neuropsychopharmacology 45(3): 462\u2013471. https:\/\/doi.org\/10.1038\/s41386-019-0569-3","DOI":"10.1038\/s41386-019-0569-3"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Hovens JE Van der Ploeg HM Bramsen I et al. (1994) The development of the self-rating inventory for posttraumatic stress disorder. Acta Psychiatrica Scandinavica 90(3): 172\u2013183. https:\/\/doi.org\/10.1111\/j.1600-0447.1994.tb01574.x","DOI":"10.1111\/j.1600-0447.1994.tb01574.x"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Hovmand OR Poulsen ED Arnfred (2024) Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. Journal of Psychopharmacology 38(1): 19\u201332. https:\/\/doi.org\/10.1177\/02698811231200019","DOI":"10.1177\/02698811231200019"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1037\/10004-000"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Jerome L Feduccia AA Wang JB et al. (2020) Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 237(8): 2485\u20132497. https:\/\/doi.org\/10.1007\/s00213-020-05548-2","DOI":"10.1007\/s00213-020-05548-2"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Ko K Knight G Rucker JJ et al. (2022) Psychedelics mystical experience and therapeutic efficacy: A systematic review. Frontiers in Psychiatry 13: 917199. https:\/\/doi.org\/10.3389\/fpsyt.2022.917199","DOI":"10.3389\/fpsyt.2022.917199"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Liechti ME Gamma A Vollenweider FX (2001). Gender differences in the subjective effects of MDMA. Psychopharmacology 154(2): 161\u2013168. https:\/\/doi.org\/10.1007\/s002130000648","DOI":"10.1007\/s002130000648"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"MacLean KA Leoutsakos JM Johnson MW et al. (2012) Factor analysis of the Mystical Experience Questionnaire: A study of experiences occasioned by the Hallucinogen Psilocybin. Journal for the Scientific Study of Religion 51(4): 721\u2013737. https:\/\/doi.org\/10.1111\/j.1468-5906.2012.01685.x","DOI":"10.1111\/j.1468-5906.2012.01685.x"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Mitchell JM Bogenschutz M Lilienstein A et al. (2021) MDMA-assisted therapy for severe PTSD: A randomized double-blind placebo-controlled phase 3 study. Nature Medicine 27(6): 1025\u20131033. https:\/\/doi.org\/10.1038\/s41591-021-01336-3","DOI":"10.1038\/s41591-021-01336-3"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Mitchell JM Ot\u2019alora GM van der Kolk B et al. (2023) MDMA-assisted therapy for moderate to severe PTSD: A randomized placebo-controlled phase 3 trial. Nature Medicine 29(10): 2473\u20132480. https:\/\/doi.org\/10.1038\/s41591-023-02565-4","DOI":"10.1038\/s41591-023-02565-4"},{"key":"e_1_3_3_21_1","volume-title":"A Manual for MDMA-assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder; Version 8.1","author":"Mithoefer MC","year":"2017","unstructured":"Mithoefer MC (2017) A Manual for MDMA-assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder; Version 8.1. Multidisciplinary Association for Psychedelic Studies."},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Mithoefer MC Feduccia AA Jerome L et al. (2019) MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology 236(9): 2735\u20132745. https:\/\/doi.org\/10.1007\/s00213-019-05249-5","DOI":"10.1007\/s00213-019-05249-5"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Nichols DE (1986) Differences between the mechanism of action of MDMA MBDB and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. Journal of Psychoactive Drugs 18(4): 305\u2013313. https:\/\/doi.org\/10.1080\/02791072.1986.10472362","DOI":"10.1080\/02791072.1986.10472362"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Poyatos L Papaseit E Olesti E et al. (2021) A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure. Biology 10(8): 788. https:\/\/doi.org\/10.3390\/biology10080788","DOI":"10.3390\/biology10080788"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Preacher KJ Hayes AF (2008) Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behavior Research Methods 40(3): 879\u2013891. https:\/\/doi.org\/10.3758\/BRM.40.3.879","DOI":"10.3758\/BRM.40.3.879"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Romeo B Kervadec E Fauvel B et al. (2025) The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews 172: Article 106086. https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106086","DOI":"10.1016\/j.neubiorev.2025.106086"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","unstructured":"Schmid Y Gasser P Oehen P et al. (2021) Acute subjective effects in LSD-and MDMA-assisted psychotherapy. Journal of Psychopharmacology 35(4): 362\u2013374. https:\/\/doi.org\/10.1177\/0269881120959604","DOI":"10.1177\/0269881120959604"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Schoemann AM Boulton AJ Short SD (2017) Determining power and sample size for simple and complex mediation models. Social Psychological and Personality Science 8(4) 379\u2013386. https:\/\/doi.org\/10.1177\/1948550617715068","DOI":"10.1177\/1948550617715068"},{"key":"e_1_3_3_30_1","volume-title":"Mysticism and Philosophy","author":"Stace WT","year":"1960","unstructured":"Stace WT (1960) Mysticism and Philosophy. St. Martin\u2019s Press."},{"key":"e_1_3_3_31_1","doi-asserted-by":"crossref","unstructured":"Stocker K Liechti ME (2024). Methylenedioxy-methamphetamine is a connectogen with empathogenic entactogenic and still further connective properties: It is time to reconcile \u201cthe great entactogen\u2014empathogen debate\u201d. Journal of Psychopharmacology 38(8): 685\u2013689. https:\/\/doi.org\/10.1177\/02698811241245855.","DOI":"10.1177\/02698811241265352"},{"key":"e_1_3_3_32_1","doi-asserted-by":"crossref","unstructured":"Stocker K Hartmann M Ley L et al. (2024) The revival of the psychedelic experience scale: Revealing its extended-mystical visual and distressing experiential spectrum with LSD and psilocybin studies. Journal of Psychopharmacology 38(1): 80\u2013100. https:\/\/doi.org\/10.1177\/02698811231220725","DOI":"10.1177\/02698811231199112"},{"key":"e_1_3_3_33_1","doi-asserted-by":"crossref","unstructured":"Vollenweider FX (2001) Brain mechanisms of hallucinogens and entactogens. Dialogues in clinical Neuroscience 3(4): 265\u2013279. https:\/\/doi.org\/10.31887\/DCNS.2001.3.4\/fxvollenweider","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider"},{"key":"e_1_3_3_34_1","doi-asserted-by":"crossref","unstructured":"Weathers FW Keane TM Davidson JR (2001) Clinician-Administered PTSD Scale: A review of the first ten years of research. Depression and Anxiety 13(3): 132\u2013156. https:\/\/doi.org\/10.1002\/da.1029.","DOI":"10.1002\/da.1029"},{"key":"e_1_3_3_35_1","doi-asserted-by":"crossref","unstructured":"van Wel JH Kuypers KP Theunissen EL et al. (2012) Effects of acute MDMA intoxication on mood and impulsivity: Role of the 5-HT2 and 5-HT1 receptors. PLoS ONE 7(7): e40187. https:\/\/doi.org\/10.1371\/journal.pone.0040187","DOI":"10.1371\/journal.pone.0040187"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261464502","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261464502","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261464502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:46:59Z","timestamp":1786204019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261464502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":34,"alternative-id":["10.1177\/02698811261464502"],"URL":"https:\/\/doi.org\/10.1177\/02698811261464502","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"02698811261464502"}}